Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dofetilide
Drug ID BADD_D00701
Description Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Indications and Usage For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Marketing Status Prescription
ATC Code C01BD04
DrugBank ID DB00204
KEGG ID D00647
MeSH ID C063533
PubChem ID 71329
TTD Drug ID D0NW3X
NDC Product Code 62756-179; 42794-044; 16714-841; 69539-131; 16729-490; 51862-125; 72205-040; 69539-132; 16714-842; 42291-411; 69452-132; 72205-039; 69452-131; 69766-022; 69452-133; 47335-061; 63190-0670; 16714-840; 42291-413; 42794-045; 0069-5800; 72205-041; 59651-038; 49812-0261; 76055-0013; 59651-118; 47335-062; 0069-5810; 51862-025; 16729-492; 0904-6681; 42413-0170; 59651-120; 63190-0680; 0069-5820; 59651-119; 70595-001; 0904-6683; 29902-0014; 47335-063; 16729-491; 14096-192; 42794-046; 42291-412; 63278-1079; 69539-130; 51862-005; 0904-6682; 50137-4245
Synonyms dofetilide | 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane | 1-MSPMPE | Tikosyn | UK 68798 | UK-68,798
Chemical Information
Molecular Formula C19H27N3O5S2
CAS Registry Number 115256-11-6
SMILES CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.000556%
Angina pectoris02.02.02.002; 24.04.04.0020.000371%
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Application site reaction08.02.01.006; 12.07.01.006--Not Available
Arrhythmia02.03.02.0010.004080%Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.0030.000556%Not Available
Asthenia08.01.01.0010.002411%Not Available
Asthma10.01.03.010; 22.03.01.0020.000371%Not Available
Atrial fibrillation02.03.03.0020.008531%
Atrial flutter02.03.03.0030.000371%
Atrial tachycardia02.03.03.0040.000371%
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Blood creatinine increased13.13.01.0040.000742%
Blood magnesium decreased13.11.01.0080.000927%Not Available
Blood potassium decreased13.11.01.0100.000371%Not Available
Blood pressure abnormal13.14.03.0010.000371%Not Available
Blood pressure decreased13.14.03.0020.000927%Not Available
Blood pressure increased13.14.03.0050.001113%Not Available
Blood sodium decreased13.11.01.0120.000371%Not Available
Bone disorder15.02.04.0040.000556%Not Available
Bradycardia02.03.02.0020.000927%Not Available
Bronchitis11.01.09.001; 22.07.01.0010.000742%
Bundle branch block02.03.01.009--Not Available
Burning sensation08.01.09.029; 17.02.06.0010.000927%Not Available
Cardiac arrest02.03.04.0010.000532%
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene